Comparison of Efficacy and Economic Value of Prandilin 25 and Humalog Mix 25 in Patients with Newly Diagnosed Type 2 Diabetes by a Continuous Glucose Monitoring System

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Yong LuoJian Zhu

Abstract

To determine the clinical efficacy and economic value of insulin lispro 25-Prandilin 25 vs. insulin lispro 25-Humalog mix 25 in treatment of newly diagnosed type 2 diabetes mellitus (T2DM) by a continuous glucose monitoring system (CGMS). This was a single-center, randomized, case-crossover clinical trial. Participants were randomly allocated to two groups and underwent two kinds of insulin lispro 25 treatment separated by a 1-day washout period. In total, 81 patients with newly diagnosed T2DM with hemoglobin A1c (HbA1c) above 9% were hospitalized and randomly divided to receive Prandilin 25/Humalog mix 25 or Humalog mix 25/Prandilin 25 treatment. All participants were subjected to metformin therapy simultaneously. Glycemic control was reached after 7-8 days Prandilin 25 or Humalog mix 25 treatment; each patient received continuous glucose monitoring (CGM) for 5 consecutive days (from day 1 to day 5). On day 3 of CGM performance, Prandilin 25 treatment was switched to Humalog mix 25 treatment at the same dosage or vice versa. Parameters representing glycemic variability (GV) and postprandial glucose excursions, including 24-h mean blood glucose (24hMBG), 24-h standard deviation of blood glucose (24hSDBG), 24-h mean amplitude of...Continue Reading

References

Apr 13, 2006·JAMA : the Journal of the American Medical Association·Michael Brownlee, Irl B Hirsch
Nov 27, 2008·Diabetes·Philip E Cryer
Jul 27, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·A Ceriello, M A Ihnat
Jul 4, 2012·Cardiovascular Diabetology·Lisa KitasatoMinako Yamaoka-Tojo
Nov 14, 2012·Nutrition Research·Eunice Mah, Richard S Bruno
Nov 28, 2012·Diabetes Technology & Therapeutics·Simon Lebech CichoszTroels Krarup Hansen
Oct 17, 2013·Journal of Diabetes·Svetlana ElizarovaBruce H R Wolffenbuttel
Jan 1, 2013·Diagnostics·Sandeep Kumar Vashist
Mar 24, 2016·Diabetes Care·Muh Geot WongUNKNOWN ADVANCE-ON Collaborative Group
Jul 28, 2016·Diabetes/metabolism Research and Reviews·Jianping WengUNKNOWN Chinese Diabetes Society
Dec 9, 2016·Journal of Diabetes Investigation·Wayne H-H SheuThomas Lew
Dec 21, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Feng-Fei LiJian-Hua Ma
May 1, 2017·The Lancet. Diabetes & Endocrinology·Christian BommerSebastian Vollmer
May 1, 2017·The Lancet. Diabetes & Endocrinology·Ping Zhang, Edward Gregg
Sep 19, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Feng-Fei LiJian-Hua Ma
Feb 7, 2018·Endocrinology and Metabolism Clinics of North America·Marian Sue KirkmanMary T Korytkowski
Feb 25, 2018·Diabetes Care·Christian BommerSebastian Vollmer
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda

❮ Previous
Next ❯

Citations

Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Arina D PuspitasariBudi Suprapti
Jan 6, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yong LuoJian Zhu

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

CGMS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.